0

Close
 
Upcoming Allied Market Research
2023
Bone Marrow Transplant Market

Bone Marrow Transplant Market: Global Opportunity Analysis and Industry Forecast, 2023-2030 Market

LS : Healthcare
Report Code: A10466
Nov 2023 | Pages: NA
Tables: NA
Charts: NA

  • Formats*:

  • pdf

    Single User License, Five User
    License & Enterprise User License

  • xls

    Data Pack Excel License

  • ppt

    It comes with the additional cost
    of $2500.00 contact sales.
 

COVID-19

Pandemic disrupted the entire world and affected many industries.

Get detailed COVID-19 impact analysis on the Bone Marrow Transplant Market

Request Now !

Bone Marrow Transplant Market Outlook - 2027

Bone marrow transplant is a procedure to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Bone marrow is the soft, fatty tissue inside the bones. It produces blood cells. Stem cells are immature cells in the bone marrow that give rise to all of our different blood cells. Before the transplant, chemotherapy, radiation, or both may be given. This may be done in two ways such as ablative (myeloablative) treatment and reduced intensity treatment. This allows older people and those with other health problems to have a transplant. A stem cell transplant is usually done after chemotherapy and radiation is complete. The stem cells are delivered into the bloodstream, usually through a tube called a central venous catheter. The process is similar to getting a blood transfusion. The stem cells travel through the blood into the bone marrow. Most times, no surgery is needed.

Bone-marrow-transplant

COVID-19 scenario analysis:

Coronavirus disease 2019 (COVID-19) has created an economic crisis along with a healthcare crisis. COVID-19 pandemic has stretched healthcare system worldwide, wherein developed countries are expected to witness economic recession. The COVID-19 pandemic has an adverse impact on the healthcare system, resulting in 50% to 70% drop in revenue from March 2020. Many small hospitals, clinics, and nursing homes have been forced to shut their operations. Social distancing and localized curfews have resulted in delayed elective surgical procedures. In addition, visa cancellations have led to a hiatus in medical tourism and can negatively impact the healthcare services market growth.

Top impacting factors: Market scenario analysis, trends, drivers, and impact analysis

The major factor affecting the industry includes surge in the prevalence of blood cancer and other blood related diseases. This statistics is anticipated to help the industry propel over the forecast period. Furthermore, steep increase in the development of stem cell cryopreservation, which is the need of the hour, would contribute the bone marrow transplant market to gain traction in the coming years. However, lack of reimbursement policies for mainly organ transplantation procedures in emerging economies and developed countries is expected to hamper the growth of the industry in the next few years.

Increase in R&D activities to boost the market

The increase in the number of product launches would help the industry to flourish over the forecast period. For instance, in May 2020, Gamida Cell Ltd., an advanced cell therapy company committed to finding cures for blood cancers and serious blood diseases, declared positive topline results from its Phase 3 clinical study evaluating the safety and efficacy of omidubicel, an investigational advanced cell therapy in development as a potential life-saving treatment option for patients in need of bone marrow transplant.

The median time to neutrophil engraftment was 12 days for patients randomized to omidubicel compared to 22 days for the comparator group (p<0.001). Neutrophil engraftment is a measure of how quickly the stem cells that a patient receives in a transplant are established and begin to make healthy new cells. Rapid neutrophil engraftment has been associated with fewer infections and shorter hospitalizations.

Surge in number of mergers and acquisitions to propel the market

The increase in the number of mergers & acquisitions is anticipated to help the industry boost in the coming years. For instance, in September 2017, Inotek Pharmaceuticals entered into a definitive merger agreement with Rocket Pharmaceuticals, a U.S.-based gene therapy company. Subject to shareholder approval, the combined company retains the name Rocket Pharmaceuticals and will be headquartered in New York City.

The combined company will focus on developing and advancing its pipeline of gene therapies based on lentiviral virus (LVV) and adeno-associated virus (AAV) gene therapy platforms, with a focus on treating devastating rare diseases.

Furthermore, in November 2019, Lonza Group Ltd. partnered with Cryoport, Inc. in the cell and gene therapy field and across Lonza's 'vein-to-vein' delivery network.

Key benefits of the report:

  • This study presents the analytical depiction of the global bone marrow transplant market along with the current trends and future estimations to determine the imminent investment pockets.
  • The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the global bone marrow transplant market share.
  • The current market is quantitatively analyzed to highlight the global bone marrow transplant market growth scenario.
  • Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market.
  • The report provides a detailed global bone marrow transplant market analysis based on competitive intensity and how the competition will take shape in coming years.

Questions answered in the market research report:

  • Which are the leading market players active in the market?
  • What are the current trends that will influence the market in the next few years?
  • What are the driving factors, restraints, and opportunities of the market?
  • What are the projections for the future that would help in taking further strategic steps?

 Bone Marrow Transplant Market: Global Opportunity Analysis and Industry Forecast, 2020–2027 Report Highlights

Aspects Details
By Treatment Type
  • Myelodysplastic Syndrome
  • Myeloproliferative neoplasms
  • Leukemia
  • Lymphoma
  • Aplastic Anemia
  • Myeloma
  • Solid Tumors
  • Sickle Cell Anemia
  • Thalassemia
  • Others
By End User
  • Hospitals
  • Multi-Specialty Clinics
  • Ambulatory Surgical Centers
By Region
  • North America  (U.S., Canada, Mexico)
  • Europe  (France, Germany, Italy, Spain, UK, Rest of Europe)
  • Asia-Pacific  (China, Japan, India, South Korea, Australia, Rest of Asia-Pacific)
  • LAMEA  (Brazil, South Africa, Saudi Arabia, Rest of LAMEA)
Key Market Players STEMCELL Technologies,, Sanofi-Aventis LLC,, Lonza Group Ltd.,, AllCells LLC,, Conversant Bio, Cellular Dynamics International, Merck Millipore Corporation,, American Type Culture Collection (ATCC) Inc., ReachBio LLC., ATCC Inc.
 

  • CHAPTER 1: INTRODUCTION

    • 1.1. Report Description

    • 1.2. Key Market Segments

    • 1.3. Key Benefits

    • 1.4. Research Methodology

      • 1.4.1. Primary Research

      • 1.4.2. Secondary Research

      • 1.4.3. Analyst Tools and Models

  • CHAPTER 2: EXECUTIVE SUMMARY

    • 2.1. CXO Perspective

  • CHAPTER 3: MARKET LANDSCAPE

    • 3.1. Market Definition and Scope

    • 3.2. Key Findings

      • 3.2.1. Top Investment Pockets

      • 3.2.2. Top Winning Strategies

    • 3.3. Porter's Five Forces Analysis

      • 3.3.1. Bargaining Power of Suppliers

      • 3.3.2. Threat of New Entrants

      • 3.3.3. Threat of Substitutes

      • 3.3.4. Competitive Rivalry

      • 3.3.5. Bargaining Power among Buyers

    • 3.5. Market Dynamics

      • 3.5.1. Drivers

      • 3.5.2. Restraints

      • 3.5.3. Opportunities

    • 3.6. COVID-19 Impact Analysis

  • CHAPTER 4: BONE MARROW TRANSPLANT MARKET, BY TREATMENT TYPE

    • 4.1. Market Overview

      • 4.1.1 Market Size and Forecast, By Treatment Type

    • 4.2. Myelodysplastic Syndrome

      • 4.2.1. Key Market Trends, Growth Factors and Opportunities

      • 4.2.2. Market Size and Forecast, By Region

      • 4.2.3. Market Share Analysis, By Country

    • 4.3. Myeloproliferative Neoplasms

      • 4.3.1. Key Market Trends, Growth Factors and Opportunities

      • 4.3.2. Market Size and Forecast, By Region

      • 4.3.3. Market Share Analysis, By Country

    • 4.4. Leukemia

      • 4.4.1. Key Market Trends, Growth Factors and Opportunities

      • 4.4.2. Market Size and Forecast, By Region

      • 4.4.3. Market Share Analysis, By Country

    • 4.5. Lymphoma

      • 4.5.1. Key Market Trends, Growth Factors and Opportunities

      • 4.5.2. Market Size and Forecast, By Region

      • 4.5.3. Market Share Analysis, By Country

    • 4.6. Aplastic Anemia

      • 4.6.1. Key Market Trends, Growth Factors and Opportunities

      • 4.6.2. Market Size and Forecast, By Region

      • 4.6.3. Market Share Analysis, By Country

    • 4.7. Myeloma

      • 4.7.1. Key Market Trends, Growth Factors and Opportunities

      • 4.7.2. Market Size and Forecast, By Region

      • 4.7.3. Market Share Analysis, By Country

    • 4.8. Solid Tumors

      • 4.8.1. Key Market Trends, Growth Factors and Opportunities

      • 4.8.2. Market Size and Forecast, By Region

      • 4.8.3. Market Share Analysis, By Country

    • 4.9. Sickle Cell Anemia

      • 4.9.1. Key Market Trends, Growth Factors and Opportunities

      • 4.9.2. Market Size and Forecast, By Region

      • 4.9.3. Market Share Analysis, By Country

    • 4.10. Thalassemia

      • 4.10.1. Key Market Trends, Growth Factors and Opportunities

      • 4.10.2. Market Size and Forecast, By Region

      • 4.10.3. Market Share Analysis, By Country

    • 4.11. Others

      • 4.11.1. Key Market Trends, Growth Factors and Opportunities

      • 4.11.2. Market Size and Forecast, By Region

      • 4.11.3. Market Share Analysis, By Country

  • CHAPTER 5: BONE MARROW TRANSPLANT MARKET, BY END USER

    • 5.1. Market Overview

      • 5.1.1 Market Size and Forecast, By End User

    • 5.2. Hospitals

      • 5.2.1. Key Market Trends, Growth Factors and Opportunities

      • 5.2.2. Market Size and Forecast, By Region

      • 5.2.3. Market Share Analysis, By Country

    • 5.3. Multi-Specialty Clinics

      • 5.3.1. Key Market Trends, Growth Factors and Opportunities

      • 5.3.2. Market Size and Forecast, By Region

      • 5.3.3. Market Share Analysis, By Country

    • 5.4. Ambulatory Surgical Centers

      • 5.4.1. Key Market Trends, Growth Factors and Opportunities

      • 5.4.2. Market Size and Forecast, By Region

      • 5.4.3. Market Share Analysis, By Country

  • CHAPTER 6: BONE MARROW TRANSPLANT MARKET, BY REGION

    • 6.1. Market Overview

      • 6.1.1 Market Size and Forecast, By Region

    • 6.2. North America

      • 6.2.1. Key Market Trends and Opportunities

      • 6.2.2. Market Size and Forecast, By Treatment Type

      • 6.2.3. Market Size and Forecast, By End User

      • 6.2.4. Market Size and Forecast, By Country

      • 6.2.5. U.S. Bone Marrow Transplant Market

        • 6.2.5.1. Market Size and Forecast, By Treatment Type
        • 6.2.5.2. Market Size and Forecast, By End User

      • 6.2.6. Canada Bone Marrow Transplant Market

        • 6.2.6.1. Market Size and Forecast, By Treatment Type
        • 6.2.6.2. Market Size and Forecast, By End User

      • 6.2.7. Mexico Bone Marrow Transplant Market

        • 6.2.7.1. Market Size and Forecast, By Treatment Type
        • 6.2.7.2. Market Size and Forecast, By End User

    • 6.3. Europe

      • 6.3.1. Key Market Trends and Opportunities

      • 6.3.2. Market Size and Forecast, By Treatment Type

      • 6.3.3. Market Size and Forecast, By End User

      • 6.3.4. Market Size and Forecast, By Country

      • 6.3.5. France Bone Marrow Transplant Market

        • 6.3.5.1. Market Size and Forecast, By Treatment Type
        • 6.3.5.2. Market Size and Forecast, By End User

      • 6.3.6. Germany Bone Marrow Transplant Market

        • 6.3.6.1. Market Size and Forecast, By Treatment Type
        • 6.3.6.2. Market Size and Forecast, By End User

      • 6.3.7. Italy Bone Marrow Transplant Market

        • 6.3.7.1. Market Size and Forecast, By Treatment Type
        • 6.3.7.2. Market Size and Forecast, By End User

      • 6.3.8. Spain Bone Marrow Transplant Market

        • 6.3.8.1. Market Size and Forecast, By Treatment Type
        • 6.3.8.2. Market Size and Forecast, By End User

      • 6.3.9. UK Bone Marrow Transplant Market

        • 6.3.9.1. Market Size and Forecast, By Treatment Type
        • 6.3.9.2. Market Size and Forecast, By End User

      • 6.3.10. Russia Bone Marrow Transplant Market

        • 6.3.10.1. Market Size and Forecast, By Treatment Type
        • 6.3.10.2. Market Size and Forecast, By End User

      • 6.3.11. Rest Of Europe Bone Marrow Transplant Market

        • 6.3.11.1. Market Size and Forecast, By Treatment Type
        • 6.3.11.2. Market Size and Forecast, By End User

    • 6.4. Asia-Pacific

      • 6.4.1. Key Market Trends and Opportunities

      • 6.4.2. Market Size and Forecast, By Treatment Type

      • 6.4.3. Market Size and Forecast, By End User

      • 6.4.4. Market Size and Forecast, By Country

      • 6.4.5. China Bone Marrow Transplant Market

        • 6.4.5.1. Market Size and Forecast, By Treatment Type
        • 6.4.5.2. Market Size and Forecast, By End User

      • 6.4.6. Japan Bone Marrow Transplant Market

        • 6.4.6.1. Market Size and Forecast, By Treatment Type
        • 6.4.6.2. Market Size and Forecast, By End User

      • 6.4.7. India Bone Marrow Transplant Market

        • 6.4.7.1. Market Size and Forecast, By Treatment Type
        • 6.4.7.2. Market Size and Forecast, By End User

      • 6.4.8. South Korea Bone Marrow Transplant Market

        • 6.4.8.1. Market Size and Forecast, By Treatment Type
        • 6.4.8.2. Market Size and Forecast, By End User

      • 6.4.9. Australia Bone Marrow Transplant Market

        • 6.4.9.1. Market Size and Forecast, By Treatment Type
        • 6.4.9.2. Market Size and Forecast, By End User

      • 6.4.10. Thailand Bone Marrow Transplant Market

        • 6.4.10.1. Market Size and Forecast, By Treatment Type
        • 6.4.10.2. Market Size and Forecast, By End User

      • 6.4.11. Malaysia Bone Marrow Transplant Market

        • 6.4.11.1. Market Size and Forecast, By Treatment Type
        • 6.4.11.2. Market Size and Forecast, By End User

      • 6.4.12. Indonesia Bone Marrow Transplant Market

        • 6.4.12.1. Market Size and Forecast, By Treatment Type
        • 6.4.12.2. Market Size and Forecast, By End User

      • 6.4.13. Rest of Asia Pacific Bone Marrow Transplant Market

        • 6.4.13.1. Market Size and Forecast, By Treatment Type
        • 6.4.13.2. Market Size and Forecast, By End User

    • 6.5. LAMEA

      • 6.5.1. Key Market Trends and Opportunities

      • 6.5.2. Market Size and Forecast, By Treatment Type

      • 6.5.3. Market Size and Forecast, By End User

      • 6.5.4. Market Size and Forecast, By Country

      • 6.5.5. Brazil Bone Marrow Transplant Market

        • 6.5.5.1. Market Size and Forecast, By Treatment Type
        • 6.5.5.2. Market Size and Forecast, By End User

      • 6.5.6. South Africa Bone Marrow Transplant Market

        • 6.5.6.1. Market Size and Forecast, By Treatment Type
        • 6.5.6.2. Market Size and Forecast, By End User

      • 6.5.7. Saudi Arabia Bone Marrow Transplant Market

        • 6.5.7.1. Market Size and Forecast, By Treatment Type
        • 6.5.7.2. Market Size and Forecast, By End User

      • 6.5.8. UAE Bone Marrow Transplant Market

        • 6.5.8.1. Market Size and Forecast, By Treatment Type
        • 6.5.8.2. Market Size and Forecast, By End User

      • 6.5.9. Argentina Bone Marrow Transplant Market

        • 6.5.9.1. Market Size and Forecast, By Treatment Type
        • 6.5.9.2. Market Size and Forecast, By End User

      • 6.5.10. Rest of LAMEA Bone Marrow Transplant Market

        • 6.5.10.1. Market Size and Forecast, By Treatment Type
        • 6.5.10.2. Market Size and Forecast, By End User

  • CHAPTER 7: COMPETITIVE LANDSCAPE

    • 7.1. Introduction

    • 7.2. Top Winning Strategies

    • 7.3. Product Mapping Of Top 10 Player

    • 7.4. Competitive Dashboard

    • 7.5. Competitive Heatmap

    • 7.6. Top Player Positioning,2022

  • CHAPTER 8: COMPANY PROFILES

    • 8.1. Lonza Group Ltd.,

      • 8.1.1. Company Overview

      • 8.1.2. Key Executives

      • 8.1.3. Company Snapshot

      • 8.1.4. Operating Business Segments

      • 8.1.5. Product Portfolio

      • 8.1.6. Business Performance

      • 8.1.7. Key Strategic Moves and Developments

    • 8.2. Sanofi-Aventis LLC,

      • 8.2.1. Company Overview

      • 8.2.2. Key Executives

      • 8.2.3. Company Snapshot

      • 8.2.4. Operating Business Segments

      • 8.2.5. Product Portfolio

      • 8.2.6. Business Performance

      • 8.2.7. Key Strategic Moves and Developments

    • 8.3. AllCells LLC,

      • 8.3.1. Company Overview

      • 8.3.2. Key Executives

      • 8.3.3. Company Snapshot

      • 8.3.4. Operating Business Segments

      • 8.3.5. Product Portfolio

      • 8.3.6. Business Performance

      • 8.3.7. Key Strategic Moves and Developments

    • 8.4. Merck Millipore Corporation,

      • 8.4.1. Company Overview

      • 8.4.2. Key Executives

      • 8.4.3. Company Snapshot

      • 8.4.4. Operating Business Segments

      • 8.4.5. Product Portfolio

      • 8.4.6. Business Performance

      • 8.4.7. Key Strategic Moves and Developments

    • 8.5. STEMCELL Technologies,

      • 8.5.1. Company Overview

      • 8.5.2. Key Executives

      • 8.5.3. Company Snapshot

      • 8.5.4. Operating Business Segments

      • 8.5.5. Product Portfolio

      • 8.5.6. Business Performance

      • 8.5.7. Key Strategic Moves and Developments

    • 8.6. American Type Culture Collection (ATCC) Inc.

      • 8.6.1. Company Overview

      • 8.6.2. Key Executives

      • 8.6.3. Company Snapshot

      • 8.6.4. Operating Business Segments

      • 8.6.5. Product Portfolio

      • 8.6.6. Business Performance

      • 8.6.7. Key Strategic Moves and Developments

    • 8.7. ATCC Inc.

      • 8.7.1. Company Overview

      • 8.7.2. Key Executives

      • 8.7.3. Company Snapshot

      • 8.7.4. Operating Business Segments

      • 8.7.5. Product Portfolio

      • 8.7.6. Business Performance

      • 8.7.7. Key Strategic Moves and Developments

    • 8.8. Cellular Dynamics International

      • 8.8.1. Company Overview

      • 8.8.2. Key Executives

      • 8.8.3. Company Snapshot

      • 8.8.4. Operating Business Segments

      • 8.8.5. Product Portfolio

      • 8.8.6. Business Performance

      • 8.8.7. Key Strategic Moves and Developments

    • 8.9. ReachBio LLC.

      • 8.9.1. Company Overview

      • 8.9.2. Key Executives

      • 8.9.3. Company Snapshot

      • 8.9.4. Operating Business Segments

      • 8.9.5. Product Portfolio

      • 8.9.6. Business Performance

      • 8.9.7. Key Strategic Moves and Developments

    • 8.10. Conversant Bio

      • 8.10.1. Company Overview

      • 8.10.2. Key Executives

      • 8.10.3. Company Snapshot

      • 8.10.4. Operating Business Segments

      • 8.10.5. Product Portfolio

      • 8.10.6. Business Performance

      • 8.10.7. Key Strategic Moves and Developments

  • LIST OF TABLES

  • TABLE 1. GLOBAL BONE MARROW TRANSPLANT MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 2. GLOBAL BONE MARROW TRANSPLANT MARKET FOR MYELODYSPLASTIC SYNDROME, BY REGION, 2022-2032 ($MILLION)
  • TABLE 3. GLOBAL BONE MARROW TRANSPLANT MARKET FOR MYELOPROLIFERATIVE NEOPLASMS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 4. GLOBAL BONE MARROW TRANSPLANT MARKET FOR LEUKEMIA, BY REGION, 2022-2032 ($MILLION)
  • TABLE 5. GLOBAL BONE MARROW TRANSPLANT MARKET FOR LYMPHOMA, BY REGION, 2022-2032 ($MILLION)
  • TABLE 6. GLOBAL BONE MARROW TRANSPLANT MARKET FOR APLASTIC ANEMIA, BY REGION, 2022-2032 ($MILLION)
  • TABLE 7. GLOBAL BONE MARROW TRANSPLANT MARKET FOR MYELOMA, BY REGION, 2022-2032 ($MILLION)
  • TABLE 8. GLOBAL BONE MARROW TRANSPLANT MARKET FOR SOLID TUMORS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 9. GLOBAL BONE MARROW TRANSPLANT MARKET FOR SICKLE CELL ANEMIA, BY REGION, 2022-2032 ($MILLION)
  • TABLE 10. GLOBAL BONE MARROW TRANSPLANT MARKET FOR THALASSEMIA, BY REGION, 2022-2032 ($MILLION)
  • TABLE 11. GLOBAL BONE MARROW TRANSPLANT MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 12. GLOBAL BONE MARROW TRANSPLANT MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 13. GLOBAL BONE MARROW TRANSPLANT MARKET FOR HOSPITALS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 14. GLOBAL BONE MARROW TRANSPLANT MARKET FOR MULTI-SPECIALTY CLINICS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 15. GLOBAL BONE MARROW TRANSPLANT MARKET FOR AMBULATORY SURGICAL CENTERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 16. GLOBAL BONE MARROW TRANSPLANT MARKET, BY REGION, 2022-2032 ($MILLION)
  • TABLE 17. NORTH AMERICA BONE MARROW TRANSPLANT, BY REGION, 2022-2032 ($MILLION)
  • TABLE 18. NORTH AMERICA BONE MARROW TRANSPLANT, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 19. NORTH AMERICA BONE MARROW TRANSPLANT, BY END USER, 2022-2032 ($MILLION)
  • TABLE 20. U.S. BONE MARROW TRANSPLANT, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 21. U.S. BONE MARROW TRANSPLANT, BY END USER, 2022-2032 ($MILLION)
  • TABLE 22. CANADA BONE MARROW TRANSPLANT, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 23. CANADA BONE MARROW TRANSPLANT, BY END USER, 2022-2032 ($MILLION)
  • TABLE 24. MEXICO BONE MARROW TRANSPLANT, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 25. MEXICO BONE MARROW TRANSPLANT, BY END USER, 2022-2032 ($MILLION)
  • TABLE 26. EUROPE BONE MARROW TRANSPLANT, BY REGION, 2022-2032 ($MILLION)
  • TABLE 27. EUROPE BONE MARROW TRANSPLANT, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 28. EUROPE BONE MARROW TRANSPLANT, BY END USER, 2022-2032 ($MILLION)
  • TABLE 29. FRANCE BONE MARROW TRANSPLANT, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 30. FRANCE BONE MARROW TRANSPLANT, BY END USER, 2022-2032 ($MILLION)
  • TABLE 31. GERMANY BONE MARROW TRANSPLANT, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 32. GERMANY BONE MARROW TRANSPLANT, BY END USER, 2022-2032 ($MILLION)
  • TABLE 33. ITALY BONE MARROW TRANSPLANT, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 34. ITALY BONE MARROW TRANSPLANT, BY END USER, 2022-2032 ($MILLION)
  • TABLE 35. SPAIN BONE MARROW TRANSPLANT, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 36. SPAIN BONE MARROW TRANSPLANT, BY END USER, 2022-2032 ($MILLION)
  • TABLE 37. UK BONE MARROW TRANSPLANT, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 38. UK BONE MARROW TRANSPLANT, BY END USER, 2022-2032 ($MILLION)
  • TABLE 39. RUSSIA BONE MARROW TRANSPLANT, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 40. RUSSIA BONE MARROW TRANSPLANT, BY END USER, 2022-2032 ($MILLION)
  • TABLE 41. REST OF EUROPE BONE MARROW TRANSPLANT, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 42. REST OF EUROPE BONE MARROW TRANSPLANT, BY END USER, 2022-2032 ($MILLION)
  • TABLE 43. ASIA-PACIFIC BONE MARROW TRANSPLANT, BY REGION, 2022-2032 ($MILLION)
  • TABLE 44. ASIA-PACIFIC BONE MARROW TRANSPLANT, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 45. ASIA-PACIFIC BONE MARROW TRANSPLANT, BY END USER, 2022-2032 ($MILLION)
  • TABLE 46. CHINA BONE MARROW TRANSPLANT, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 47. CHINA BONE MARROW TRANSPLANT, BY END USER, 2022-2032 ($MILLION)
  • TABLE 48. JAPAN BONE MARROW TRANSPLANT, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 49. JAPAN BONE MARROW TRANSPLANT, BY END USER, 2022-2032 ($MILLION)
  • TABLE 50. INDIA BONE MARROW TRANSPLANT, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 51. INDIA BONE MARROW TRANSPLANT, BY END USER, 2022-2032 ($MILLION)
  • TABLE 52. SOUTH KOREA BONE MARROW TRANSPLANT, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 53. SOUTH KOREA BONE MARROW TRANSPLANT, BY END USER, 2022-2032 ($MILLION)
  • TABLE 54. AUSTRALIA BONE MARROW TRANSPLANT, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 55. AUSTRALIA BONE MARROW TRANSPLANT, BY END USER, 2022-2032 ($MILLION)
  • TABLE 56. THAILAND BONE MARROW TRANSPLANT, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 57. THAILAND BONE MARROW TRANSPLANT, BY END USER, 2022-2032 ($MILLION)
  • TABLE 58. MALAYSIA BONE MARROW TRANSPLANT, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 59. MALAYSIA BONE MARROW TRANSPLANT, BY END USER, 2022-2032 ($MILLION)
  • TABLE 60. INDONESIA BONE MARROW TRANSPLANT, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 61. INDONESIA BONE MARROW TRANSPLANT, BY END USER, 2022-2032 ($MILLION)
  • TABLE 62. REST OF ASIA PACIFIC BONE MARROW TRANSPLANT, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 63. REST OF ASIA PACIFIC BONE MARROW TRANSPLANT, BY END USER, 2022-2032 ($MILLION)
  • TABLE 64. LAMEA BONE MARROW TRANSPLANT, BY REGION, 2022-2032 ($MILLION)
  • TABLE 65. LAMEA BONE MARROW TRANSPLANT, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 66. LAMEA BONE MARROW TRANSPLANT, BY END USER, 2022-2032 ($MILLION)
  • TABLE 67. BRAZIL BONE MARROW TRANSPLANT, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 68. BRAZIL BONE MARROW TRANSPLANT, BY END USER, 2022-2032 ($MILLION)
  • TABLE 69. SOUTH AFRICA BONE MARROW TRANSPLANT, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 70. SOUTH AFRICA BONE MARROW TRANSPLANT, BY END USER, 2022-2032 ($MILLION)
  • TABLE 71. SAUDI ARABIA BONE MARROW TRANSPLANT, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 72. SAUDI ARABIA BONE MARROW TRANSPLANT, BY END USER, 2022-2032 ($MILLION)
  • TABLE 73. UAE BONE MARROW TRANSPLANT, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 74. UAE BONE MARROW TRANSPLANT, BY END USER, 2022-2032 ($MILLION)
  • TABLE 75. ARGENTINA BONE MARROW TRANSPLANT, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 76. ARGENTINA BONE MARROW TRANSPLANT, BY END USER, 2022-2032 ($MILLION)
  • TABLE 77. REST OF LAMEA BONE MARROW TRANSPLANT, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 78. REST OF LAMEA BONE MARROW TRANSPLANT, BY END USER, 2022-2032 ($MILLION)
  • TABLE 79. LONZA GROUP LTD.,: KEY EXECUTIVES
  • TABLE 80. LONZA GROUP LTD.,: COMPANY SNAPSHOT
  • TABLE 81. LONZA GROUP LTD.,: OPERATING SEGMENTS
  • TABLE 82. LONZA GROUP LTD.,: PRODUCT PORTFOLIO
  • TABLE 83. LONZA GROUP LTD.,: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 84. SANOFI-AVENTIS LLC,: KEY EXECUTIVES
  • TABLE 85. SANOFI-AVENTIS LLC,: COMPANY SNAPSHOT
  • TABLE 86. SANOFI-AVENTIS LLC,: OPERATING SEGMENTS
  • TABLE 87. SANOFI-AVENTIS LLC,: PRODUCT PORTFOLIO
  • TABLE 88. SANOFI-AVENTIS LLC,: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 89. ALLCELLS LLC,: KEY EXECUTIVES
  • TABLE 90. ALLCELLS LLC,: COMPANY SNAPSHOT
  • TABLE 91. ALLCELLS LLC,: OPERATING SEGMENTS
  • TABLE 92. ALLCELLS LLC,: PRODUCT PORTFOLIO
  • TABLE 93. ALLCELLS LLC,: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 94. MERCK MILLIPORE CORPORATION,: KEY EXECUTIVES
  • TABLE 95. MERCK MILLIPORE CORPORATION,: COMPANY SNAPSHOT
  • TABLE 96. MERCK MILLIPORE CORPORATION,: OPERATING SEGMENTS
  • TABLE 97. MERCK MILLIPORE CORPORATION,: PRODUCT PORTFOLIO
  • TABLE 98. MERCK MILLIPORE CORPORATION,: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 99. STEMCELL TECHNOLOGIES,: KEY EXECUTIVES
  • TABLE 100. STEMCELL TECHNOLOGIES,: COMPANY SNAPSHOT
  • TABLE 101. STEMCELL TECHNOLOGIES,: OPERATING SEGMENTS
  • TABLE 102. STEMCELL TECHNOLOGIES,: PRODUCT PORTFOLIO
  • TABLE 103. STEMCELL TECHNOLOGIES,: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 104. AMERICAN TYPE CULTURE COLLECTION (ATCC) INC.: KEY EXECUTIVES
  • TABLE 105. AMERICAN TYPE CULTURE COLLECTION (ATCC) INC.: COMPANY SNAPSHOT
  • TABLE 106. AMERICAN TYPE CULTURE COLLECTION (ATCC) INC.: OPERATING SEGMENTS
  • TABLE 107. AMERICAN TYPE CULTURE COLLECTION (ATCC) INC.: PRODUCT PORTFOLIO
  • TABLE 108. AMERICAN TYPE CULTURE COLLECTION (ATCC) INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 109. ATCC INC.: KEY EXECUTIVES
  • TABLE 110. ATCC INC.: COMPANY SNAPSHOT
  • TABLE 111. ATCC INC.: OPERATING SEGMENTS
  • TABLE 112. ATCC INC.: PRODUCT PORTFOLIO
  • TABLE 113. ATCC INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 114. CELLULAR DYNAMICS INTERNATIONAL: KEY EXECUTIVES
  • TABLE 115. CELLULAR DYNAMICS INTERNATIONAL: COMPANY SNAPSHOT
  • TABLE 116. CELLULAR DYNAMICS INTERNATIONAL: OPERATING SEGMENTS
  • TABLE 117. CELLULAR DYNAMICS INTERNATIONAL: PRODUCT PORTFOLIO
  • TABLE 118. CELLULAR DYNAMICS INTERNATIONAL: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 119. REACHBIO LLC.: KEY EXECUTIVES
  • TABLE 120. REACHBIO LLC.: COMPANY SNAPSHOT
  • TABLE 121. REACHBIO LLC.: OPERATING SEGMENTS
  • TABLE 122. REACHBIO LLC.: PRODUCT PORTFOLIO
  • TABLE 123. REACHBIO LLC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 124. CONVERSANT BIO: KEY EXECUTIVES
  • TABLE 125. CONVERSANT BIO: COMPANY SNAPSHOT
  • TABLE 126. CONVERSANT BIO: OPERATING SEGMENTS
  • TABLE 127. CONVERSANT BIO: PRODUCT PORTFOLIO
  • TABLE 128. CONVERSANT BIO: KEY STRATEGIC MOVES AND DEVELOPMENTS

  • LIST OF FIGURES

  • FIGURE 1. GLOBAL BONE MARROW TRANSPLANT MARKET SEGMENTATION
  • FIGURE 2. GLOBAL BONE MARROW TRANSPLANT MARKET
  • FIGURE 3. SEGMENTATION BONE MARROW TRANSPLANT MARKET
  • FIGURE 4. TOP INVESTMENT POCKET IN BONE MARROW TRANSPLANT MARKET
  • FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 8. LOW THREAT OF SUBSTITUTION
  • FIGURE 9. HIGH COMPETITIVE RIVALRY
  • FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALBONE MARROW TRANSPLANT MARKET
  • FIGURE 11. BONE MARROW TRANSPLANT MARKET SEGMENTATION, BY BY TREATMENT TYPE
  • FIGURE 12. BONE MARROW TRANSPLANT MARKET FOR MYELODYSPLASTIC SYNDROME, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 13. BONE MARROW TRANSPLANT MARKET FOR MYELOPROLIFERATIVE NEOPLASMS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 14. BONE MARROW TRANSPLANT MARKET FOR LEUKEMIA, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 15. BONE MARROW TRANSPLANT MARKET FOR LYMPHOMA, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 16. BONE MARROW TRANSPLANT MARKET FOR APLASTIC ANEMIA, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 17. BONE MARROW TRANSPLANT MARKET FOR MYELOMA, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 18. BONE MARROW TRANSPLANT MARKET FOR SOLID TUMORS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 19. BONE MARROW TRANSPLANT MARKET FOR SICKLE CELL ANEMIA, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 20. BONE MARROW TRANSPLANT MARKET FOR THALASSEMIA, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 21. BONE MARROW TRANSPLANT MARKET FOR OTHERS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 22. BONE MARROW TRANSPLANT MARKET SEGMENTATION, BY BY END USER
  • FIGURE 23. BONE MARROW TRANSPLANT MARKET FOR HOSPITALS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 24. BONE MARROW TRANSPLANT MARKET FOR MULTI-SPECIALTY CLINICS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 25. BONE MARROW TRANSPLANT MARKET FOR AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 26. TOP WINNING STRATEGIES, BY YEAR, 2020-2022*
  • FIGURE 27. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2020-2022*
  • FIGURE 28. TOP WINNING STRATEGIES, BY COMPANY, 2020-2022*
  • FIGURE 29. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 30. COMPETITIVE DASHBOARD
  • FIGURE 31. COMPETITIVE HEATMAP: BONE MARROW TRANSPLANT MARKET
  • FIGURE 32. Top player positioning, 2022
  • FIGURE 33. LONZA GROUP LTD.,: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 34. LONZA GROUP LTD.,: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 35. LONZA GROUP LTD.,: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 36. SANOFI-AVENTIS LLC,: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 37. SANOFI-AVENTIS LLC,: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 38. SANOFI-AVENTIS LLC,: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 39. ALLCELLS LLC,: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 40. ALLCELLS LLC,: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 41. ALLCELLS LLC,: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 42. MERCK MILLIPORE CORPORATION,: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 43. MERCK MILLIPORE CORPORATION,: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 44. MERCK MILLIPORE CORPORATION,: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 45. STEMCELL TECHNOLOGIES,: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 46. STEMCELL TECHNOLOGIES,: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 47. STEMCELL TECHNOLOGIES,: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 48. AMERICAN TYPE CULTURE COLLECTION (ATCC) INC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 49. AMERICAN TYPE CULTURE COLLECTION (ATCC) INC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 50. AMERICAN TYPE CULTURE COLLECTION (ATCC) INC.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 51. ATCC INC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 52. ATCC INC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 53. ATCC INC.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 54. CELLULAR DYNAMICS INTERNATIONAL: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 55. CELLULAR DYNAMICS INTERNATIONAL: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 56. CELLULAR DYNAMICS INTERNATIONAL: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 57. REACHBIO LLC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 58. REACHBIO LLC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 59. REACHBIO LLC.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 60. CONVERSANT BIO: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 61. CONVERSANT BIO: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 62. CONVERSANT BIO: REVENUE SHARE, BY REGION, 2032 (%)

 
 
With collective industry experience of about 200 years of its analysts and experts, Allied Market Research (AMR) encompasses most infallible research methodology for its market intelligence and industry analysis. We do not only engrave the deepest levels of markets but also sneak through its slimmest details for the purpose of our market estimates and forecasts. Our approach helps in building greater market consensus view for size, shape and industry trends within each industry segment. We carefully factor in industry trends and real developments for identifying key growth factors and future course of the market. Our research proceeds are the resultant of high quality data, expert views and analysis and high value independent opinions. Our research process is designed to deliver balanced view of the global markets and allow stakeholders to make informed decisions.

We offer our clients exhaustive research and analysis based on wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics and regional intelligence. Our in-house industry experts play instrumental role in designing analytic tools and models, tailored to the requirements of particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of our recommendations and advice. With AMR’s calibrated research process and 360` degree data-evaluation methodology, our clients are assured of receiving:

  • Consistent, valuable, robust and actionable data & analysis that can easily be referenced for strategic business planning
  • Technologically sophisticated and reliable insights through well audited and veracious research methodology
  • Sovereign research proceeds that present a tangible depiction of marketplace


With a strong methodology we are, therefore, confident that our research and analysis are most reliable and guarantees sound business planning.

Secondary research
We refer a broad array of industry sources for our secondary, which typically include; however, not limited to: Company SEC filings, annual reports, company websites, broker & financial reports and investor presentations for competitive scenario and shape of the industry

  • Patent and regulatory databases for understanding of technical & legal developments
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic new articles, web-casts and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators and relevant press releases for market estimates and forecast


Primary research
Our primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks and face-to-face interactions. We are also in professional corporate relations with various companies that allow us greater flexibility for reaching out industry participants and commentators for interviews and discussions, fulfilling following functions:

  • Validates and improves the data quality and strengthens research proceeds
  • Further develops analyst team’s market understanding and expertise
  • Supplies authentic information about market size, share, growth and forecasts


Our primary research interview and discussion panels are typically composed of most experienced industry members. These participants include; however, not limited to:

  • Chief executives and VPs of leading corporations specific to industry
  • Product and sales managers or country heads; channel partners and top level distributors; banking, investments and valuation experts Key opinion leaders (KOLs)


Analyst tools and models
AMR has developed set of analyst tools and data models to supplement and expedite the analysis process. Corresponding to markets, where there is significant lack of information and estimates, AMR’s team of experts and analyst develop specific analyst tools and industry models to translate qualitative and quantitative industry indicators into exact industry estimates. These models also allow analysts to examine the prospects and opportunities prevailing in the market to accurately forecast the course of the market.

PURCHASE OPTIONS

Call or Email us

U.S.-Canada Toll-free: +1-800-792-5285
Int'l : +1-503-894-6022
Europe : +44-845-528-1300
Email : help@alliedmarketresearch.com

Looking for Customization?

 Customization Request

Have a Question?

 Speak with Analyst

Any Confusion?

 Inquire Before Buying

Have a glance of the Report

  Enquiry Now
RELATED TAGS

Purchase Full Report of
Bone Marrow Transplant Market

Start reading.
This Report and over 66,804+ more Reports, Available with Avenue Library. T&C*.

  • Online Only
  • $3,690
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  • Free industry update
    (Within 180 days)
  • Free report update in next update cycle
  • Data Pack
  • $3,840
  • Restricted to one authorized user
  • One print only
  • Available in
    Excel
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Single User
  • $5,820
  • Restricted to one authorized user
  • One print only
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Five Users
  • $6,540
  • Limited to five authorized users
  • Print upto five copies
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle

  • Enterprise
    License/PDF

  • $9,870
  • Unlimited
    within
    company/enterprise
  • Available in Excel & PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle

  • Library
    Membership

  • $999 $ 1,175
    Per User/ Per month/ Billed annually
  • Published Content
    E-access
  • Company Profiles
    E-access
  • Newly Added Content Access
  • 10 PDF
    Downloads
  • 5 Excel Data
    Pack Downloads
  • 250 Company Profiles PDF Downloads
  • Buy Now

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

RELATED REPORTS
 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

Get Industry Data Alerts

Why Allied Market Research?

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers